cardiovascular
diseas
repres
one
lead
caus
death
global
atherosclerosi
chronic
inflammatori
patholog
character
deposit
plaqu
collect
fat
cholesterol
calcium
fibrin
cellular
wast
product
wall
arteri
domin
caus
cardiovascular
diseas
partial
ruptur
detach
plaqu
increas
risk
clog
blood
flow
ultim
lead
highli
incapacit
even
mortal
condit
myocardi
infarct
cerebrovascular
accid
exact
caus
atherosclerosi
remain
subject
discuss
connect
sever
distinct
mechan
hypothes
theori
nonetheless
despit
complex
atherosclerosi
gener
correl
level
cholesterol
plasma
hmgcoa
reductas
involv
biosynthesi
cholesterol
subject
feedback
regul
endproduct
pathway
thu
inhibit
hmgcoa
reductas
statin
becam
essenti
strategi
primari
prevent
atherosclerosi
statin
contain
dihydroxycarboxyl
acid
moieti
mimic
outcompet
natur
substrat
molecul
hmgcoa
prevent
reduct
mevalon
cholesterol
synthesi
fig
addit
cholesterollow
action
success
statin
becam
increasingli
connect
broader
pleiotrop
effect
statin
increasingli
associ
potenti
protect
effect
patholog
beyond
cardiovascular
diseas
eg
respiratori
carcinogen
viral
neurodegen
exact
offtarget
mechan
statin
along
reason
mani
patient
show
resist
class
drug
still
unknown
therefor
increas
specif
knowledg
subcellular
mechan
affect
statin
develop
sensit
tool
investig
subject
current
challeng
hot
topic
medicin
chemistri
highresolut
molecular
imag
modal
positron
emiss
tomographi
pet
togeth
sensit
nuclear
analyt
techniqu
reli
radiolabel
molecul
help
better
understand
map
biodistribut
profil
time
within
complex
live
organ
purpos
report
atorvastatin
one
wide
use
statin
prevent
cardiovascular
risk
factor
one
bestsel
drug
pharmaceut
histori
exchang
aryl
fluorid
radioisotop
enabl
radiolabel
atorvastatin
without
chang
pharmacolog
properti
howev
case
atorvastatin
electronrich
aren
classic
struggl
radiochemistri
challeng
associ
synthesi
autom
fluorinecontain
aromat
ring
within
atorvastatin
structur
electronrich
therefor
use
rutheniummedi
radiodeoxyfluorin
strategi
synthes
atorvastatin
radiotrac
may
potenti
becom
attract
tool
statinrel
research
enabl
understand
cellular
subcellular
mechan
identif
offtarget
activ
ultim
allow
select
statinresist
nonresist
patient
target
therapi
synthesi
benzyl
ether
pyrrol
intermedi
well
atorvastatin
precursor
perform
treatment
correspond
intermedi
respect
commerci
avail
primari
amin
pival
acidcatalyz
paalknorr
condens
reaction
scheme
intermedi
synthes
via
stetter
reaction
summari
keton
combin
benzaldehyd
respect
presenc
triethylamin
thiazolium
bromid
catalyst
afford
correspond
intermedi
respect
atorvastatin
obtain
precursor
near
quantit
remov
ketalest
protect
group
sidechain
sequenti
hydrochlor
acid
sodium
hydroxid
treatment
radiofluorin
atorvastatin
benzyl
ether
pyrrol
intermedi
synthes
subsequ
convert
correspond
phenol
palladium
carbon
pdc
catalyz
hydrogenolysi
scheme
coordin
ruthenium
ii
decreas
densiti
provid
activ
precursor
toward
radiodeoxyfluorin
synthesi
atorvastatin
start
convent
trap
aqueou
fluorid
produc
cyclotron
use
p
n
nuclear
reaction
anion
exchang
cartridg
chromafix
fluorid
elut
cartridg
solut
label
precursor
n
nbi
chlorid
equiv
bi
trimethylneopentylammonium
oxal
mixtur
ethanol
pivalonitril
veratrol
v
v
v
directli
reaction
vial
reaction
mixtur
heat
vigor
stir
min
afford
key
intermedi
drawback
literatur
procedur
reduc
elut
effici
anion
exchang
cartridg
besid
commerci
supplier
oxal
salt
may
hinder
good
manufacturingradiopharmaceuticalclin
practic
gmpgrppgcp
applic
synthes
radiotrac
addit
analyt
evalu
toxic
test
reliabl
establish
product
addit
may
need
compli
potenti
clinic
trial
human
patient
mention
previou
report
salt
addit
tend
reduc
yield
even
though
elut
effici
increas
thu
work
sever
readili
avail
addit
evalu
order
achiev
better
elut
altern
increas
elut
effici
minim
affect
yield
tabl
expect
test
addit
neg
effect
yield
use
bi
trimethylneopentylammonium
oxal
gave
best
overal
yield
addit
still
decreas
convers
approxim
compar
experi
without
eluent
addit
accept
altern
oxal
seem
use
commerci
avail
tetrabutylammonium
chlorid
despit
lower
elut
effici
led
similar
yield
experi
show
absenc
eluent
addit
elut
effici
doubl
revers
load
elut
cartridg
replac
cartridg
short
ptfe
tube
fill
approxim
mg
biorad
resin
fig
howev
revers
cartridg
easili
implement
autom
modul
also
sinc
minicartridg
commerci
avail
therefor
manual
prepar
might
result
signific
elut
differ
batch
batch
affect
activ
yield
led
us
evalu
differ
solvent
system
without
use
eluent
addit
increas
elut
effici
tabl
chang
solvent
use
dissolv
label
precursor
chloroimidazolium
chlorid
keep
reaction
condit
unchang
abl
improv
elut
effici
also
yield
achiev
intermedi
product
use
mixtur
methanol
veratrol
v
v
methanol
dmso
v
v
provid
best
result
howev
mixtur
veratrol
quickli
build
high
pressur
reaction
vial
associ
radioact
escap
thu
replac
veratrol
dimethylsulfoxid
dmso
safer
choic
solvent
optim
method
boost
simplifi
techniqu
avoid
addit
salt
addit
skip
need
wash
trap
fluorid
circumv
timeconsum
azeotrop
dri
consequ
radioact
loss
natur
decay
evapor
unspecif
adsorpt
reactor
surfac
use
differ
solvent
mixtur
variou
step
process
elut
amount
rucoordin
precursor
also
reduc
relat
previous
report
work
vs
optim
work
becam
evid
procedur
deviat
air
bubbl
instead
stir
absenc
mechan
mix
increas
solvent
volum
larger
reaction
vial
flatshap
bottom
one
decreas
final
yield
order
enhanc
radiolabel
effici
featur
consid
choos
suitabl
radiosynthesi
modul
addit
excit
find
rel
toler
presenc
water
allow
direct
fluorin
use
aqueou
fluorid
cyclotron
target
without
need
anion
exchang
cartridg
drawback
low
volum
aqueou
fluorid
use
limit
amount
radioact
reaction
nevertheless
potenti
suitabl
method
smallscal
product
aim
exampl
vitro
evalu
optim
procedur
translat
synthra
rnplu
radiosynthes
minim
modif
made
commerci
configur
modul
fig
unus
load
port
reaction
vial
close
perfluoroalkoxi
plug
except
one
left
open
ethylen
tetrafluoroethylen
femal
luertomal
fit
connect
exhaust
alumina
n
cartridg
water
summari
aqueou
fluorid
trap
chromafix
anion
exchang
cartridg
preactiv
sequenti
pass
ml
mgml
ml
water
dri
flow
argon
trap
effici
n
dri
resin
cartridg
helium
flow
approxim
min
trap
fluorid
elut
push
solut
rucoordin
label
precursor
n
nbi
chlorid
equiv
methanol
dmso
v
v
ml
min
cartridg
directli
reaction
vial
preheat
elut
effici
n
preheat
seem
avoid
signific
radioact
loss
seen
rapidli
increas
room
temperatur
reaction
temperatur
reaction
vial
alreadi
set
reaction
left
stir
min
produc
intermedi
yield
estim
multipli
radiotlc
convers
fluorid
radiohplc
puriti
n
ketal
tertbutyl
protect
group
remov
sequenti
treat
reaction
mixtur
ml
methanol
hcl
v
v
min
follow
addit
ml
methanol
aqueou
naoh
v
v
stir
anoth
min
hplc
analysi
reveal
complet
absenc
intermedi
reaction
mixtur
content
reaction
vial
automat
load
onto
builtin
prepar
hplc
uv
radioact
detector
collect
atorvastatin
fraction
final
solidphas
extract
spe
enabl
solvent
exchang
reformul
physiolog
inject
calcium
acet
solut
mimic
atorvastatin
calcium
prepar
therapeut
dose
drug
gener
administ
radiochem
yield
atorvastatin
n
dc
molar
activ
n
end
synthesi
activ
yield
achiev
gbq
ndc
start
gbq
aqueou
fluorid
produc
cyclotron
n
final
purifi
formul
radiotrac
compar
correspond
nonradioact
refer
standard
analyt
radiohplc
confirm
ident
fig
atorvastatin
show
radiochem
puriti
alway
higher
sign
decomposit
observ
least
h
solut
room
temperatur
incub
radiotrac
either
human
collect
clot
healthi
volunt
wistar
rat
serum
h
indic
vitro
stabil
log
measur
confirm
lipophil
radiotrac
one
describ
atorvastatin
experiment
log
ph
n
measur
accord
report
valu
log
approx
hmgcoa
reductas
highli
express
liver
subject
hormon
dietari
pharmacolog
regul
evalu
atorvastatin
rat
liver
homogen
reveal
n
radioact
found
microsom
cytosol
fraction
accord
known
enzym
distribut
radiotlc
assess
show
absenc
degrad
block
assay
use
rat
liver
section
without
standard
atorvastatin
pretreat
perform
evalu
atorvastatin
bind
select
hmgcoa
reductas
fig
comparison
atorvastatin
uptak
nontreat
treat
liver
section
show
averag
decreas
bind
radiotrac
block
p
potenti
atorvastatin
use
pet
tracer
atherosclerosi
imag
also
preliminarili
evalu
autoradiographi
aorta
normal
atherosclerot
rat
model
due
reduct
lipoprotein
clearanc
apolipoprotein
edefici
rat
fed
highcholesterol
diet
tend
develop
elev
plasma
level
cholesterol
form
atherosclerot
plaqu
incub
aorta
excis
valid
rat
model
atherosclerosi
radiotrac
show
high
atorvastatin
uptak
atherosclerot
aorta
fig
radiotrac
uptak
reduc
aorta
pretreat
standard
atorvastatin
aorta
normal
rat
averag
uptak
atherosclerot
aorta
approxim
two
time
higher
uptak
normal
aorta
baselin
level
hmgcoa
reductas
still
present
due
ubiquit
cytoplasmat
express
differ
group
statist
signific
p
normal
aorta
uptak
control
atorvastatin
treat
group
show
averag
decreas
bind
effici
radiotrac
p
compar
uptak
result
nontreat
treat
atherosclerot
aorta
averag
decreas
seen
bind
effici
radiotrac
p
work
explor
latestag
phenol
via
ruthenium
improv
previou
attempt
synthes
emitt
version
atorvastatin
follow
boron
acid
pinacol
ester
crosscoupl
latestag
fluorin
strategi
wide
clinic
prescrib
statin
evid
benefit
cardiovascular
diseas
prevent
may
play
role
condit
still
requir
elucid
adjust
use
work
rumedi
strategi
prove
improv
compar
previous
report
procedur
includ
halv
initi
label
precursor
amount
avoid
use
differ
solvent
mixtur
salt
addit
omit
fluorid
wash
solvent
remov
procedur
togeth
simplic
process
toler
varieti
solvent
includ
aqueou
solut
low
reaction
volum
use
might
result
rumedi
deoxyfluorin
strategi
suitabl
implement
emerg
techniqu
microfluidicslabonachip
radiochemistri
microdroplet
radiosynthes
autom
optim
procedur
radiofluorin
strategi
reliabl
produc
atorvastatin
isol
radiochem
yield
dc
within
synthesi
time
approxim
min
final
inject
physiolog
solut
radiotrac
obtain
suitabl
vitro
stabil
least
upon
h
radiochem
puriti
molar
activ
evalu
potenti
use
pet
imag
agent
atherosclerosi
access
radiolabel
analog
atorvastatin
allow
map
quantif
radiotrac
uptak
either
cellular
subcellular
compart
live
complex
organ
high
sensit
nuclear
analyt
imag
techniqu
atorvastatinpet
might
becom
relev
research
tool
assess
statinrel
mechan
action
discrimin
respons
nonrespons
patient
standard
atorvastatin
known
occupi
bind
site
hmgcoa
reductas
high
affin
ki
approx
nm
effect
approx
nm
thu
pretreat
liver
section
atorvastatin
hinder
access
addit
substrat
activ
site
incub
rat
liver
section
wide
known
highli
express
hmgcoa
reductas
atorvastatin
expect
select
bind
enzym
confirm
sinc
statist
signific
decreas
uptak
observ
hepat
tissu
pretreat
nonradioact
atorvastatin
hmgcoa
reductas
known
overexpress
atherosclerot
plaqu
level
correl
plaqu
instabl
contribut
risk
partial
ruptur
detach
evalu
potenti
atorvastatin
pet
tracer
atherosclerosi
autoradiographi
imag
studi
perform
excis
aorta
apolipoprotein
edefici
rat
model
design
develop
atherosclerot
plaqu
uptak
radiotrac
statist
signific
higher
atherosclerot
aorta
compar
healthi
rat
aorta
furthermor
pretreat
refer
compound
block
atorvastatin
bind
support
potenti
pet
tracer
use
specif
detect
atherosclerot
plaqu
result
sever
decad
clinic
use
toxicolog
profil
atorvastatin
wide
known
thu
first
human
studi
alreadi
envisag
nuclear
medicin
depart
hamper
toxic
issu
optim
latestag
rumedi
strategi
perform
synthesi
autom
modul
n
suitabl
radiochem
puriti
molar
activ
affin
atorvastatin
hmgcoa
reductas
potenti
use
pet
tracer
atherosclerosi
confirm
rat
liver
sampl
comparison
radiotrac
uptak
aorta
normal
atherosclerot
rat
model
radiotrac
use
tool
vitro
assess
statinrel
mechan
action
futur
clinic
trial
may
also
facilit
toxicolog
profil
alreadi
wide
character
due
extens
clinic
use
nonradioact
analog
synthes
atorvastatin
label
precursor
intermedi
compound
describ
character
support
inform
file
cyclotronproduc
aqueou
fluorid
load
onto
polystyrenedivinylbenzen
copolymersbas
anion
exchang
cartridg
chromafix
precondit
sequenti
push
ml
mgml
ml
water
dri
flow
ar
rucoordin
label
precursor
n
nbi
chlorid
equiv
without
salt
addit
see
tabl
dissolv
solvent
see
tabl
solut
use
elut
fluorid
directli
glass
wheaton
reaction
vvial
glass
reactor
synthra
rnplu
radiosynthes
contain
stir
bar
reaction
mixtur
left
vigor
stir
min
intermedi
speci
analyz
radiotlc
tlcsg
develop
hexan
ethyl
acet
v
v
rf
f
rf
radiohplc
symmetrypreptm
mm
sodium
acet
ph
b
acetonitril
min
min
min
min
min
min
flow
mlmin
rt
min
produc
final
product
ml
methanol
hcl
v
v
solut
ad
reaction
mixtur
left
stir
min
subsequ
ml
methanol
aqueou
naoh
v
v
solut
ad
reaction
mixtur
left
stir
min
product
assess
radiotlc
tlcsg
develop
ethanol
sodium
phosphat
ph
v
v
rf
f
rf
rf
radiohplc
rt
min
final
reformul
product
obtain
collect
fraction
radiohplc
symmetrypreptm
mm
sodium
acet
ph
b
acetonitril
min
min
min
min
min
min
flow
mlmin
rt
min
rt
min
dilut
ml
water
bulk
solut
pass
oasi
hlb
cc
cartridg
mg
sorbent
water
effici
trap
final
radiotrac
wash
ml
water
recov
ml
ethanol
final
dilut
ml
calcium
acet
ph
result
isoton
inject
atorvastatin
solut
qualiti
control
qc
final
radiotrac
assess
molar
activ
radiouplc
system
use
acquiti
hss
mm
column
sodium
acet
meoh
acn
v
v
v
b
sodium
acet
meoh
acn
v
v
v
min
min
min
min
min
flow
mlmin
uv
nm
rt
min
log
measur
determin
lipophil
atorvastatin
final
reformul
radiotrac
ethanol
dissolv
mixtur
pb
ph
noctanol
microcentrifug
tube
mixtur
strongli
vortex
room
temperatur
centrifug
rpm
min
triplic
sampl
organ
aqueou
phase
collect
measur
log
valu
report
averag
ratio
number
count
noctanol
upper
layer
pb
lower
layer
obtain
independ
measur
vitro
stabil
test
final
reformul
left
room
temperatur
analyz
radiohplc
radiotlc
distinct
time
point
h
vitro
stabil
assay
perform
incub
approx
mbq
ml
human
wistar
rat
serum
h
analyz
radiotlc
radiohplc
latter
case
protein
precipit
acetonitril
variou
time
point
experi
done
triplic
liver
wistar
rat
harvest
immedi
frozen
liquid
nitrogen
conserv
bind
assay
trishcl
ph
ad
thaw
rat
liver
obtain
final
concentr
mgml
mixtur
homogen
use
heidolph
diax
homogen
cool
ice
bath
liver
homogen
batch
store
bind
assay
rat
liver
homogen
trishcl
solut
evalu
nonspecif
bind
nsb
fraction
radiotrac
tube
wall
ad
centrifug
tube
trishcl
solut
contain
human
serum
albumin
ad
reach
final
volum
left
preincub
min
room
temperatur
atorvastatin
approx
mbq
ad
assay
tube
briefli
vortex
incub
min
gentl
shake
room
temperatur
incub
termin
centrifug
rotanta
hettich
zentrifugen
assay
tube
min
rpm
supernat
fraction
contain
cytosol
microsom
tube
transfer
new
tube
leav
pellet
cell
debri
origin
tube
content
nsb
assay
tube
also
pipet
new
tube
assay
tube
measur
wallac
wizard
calcul
percentag
radioact
phase
pellet
nsb
percentag
subtract
pellet
result
harvest
liver
four
wistar
rat
n
section
three
thin
mm
sagitt
slice
mm
reduc
intervari
liver
slice
divid
two
counterpart
distribut
equal
control
block
group
n
section
group
impregn
ml
phosphatebuff
salin
pb
enrich
glucos
mm
mm
mm
previous
warm
control
group
dmso
polyethylen
glycol
sorbitan
monolaur
v
v
ad
block
group
atorvastatin
mg
dmso
polyethylen
glycol
sorbitan
monolaur
v
v
ad
reach
total
concentr
mm
final
volum
ml
liver
section
left
incub
min
incub
time
atorvastatin
approx
mbq
ad
group
left
incub
h
final
total
volum
liquid
group
care
pipet
liver
slice
wash
time
ml
cold
pb
follow
ml
ice
water
slice
care
dri
imag
ge
healthcar
amersham
typhoon
autoradiographi
system
acquir
data
analyz
optiqu
softwar
quantifi
radiotrac
uptak
digit
luminesc
unit
dlu
harvest
aorta
healthi
wistar
rat
apolipoprotein
edefici
wistar
rat
model
atherosclerosi
transvers
section
segment
aortic
arch
supraren
abdomin
aorta
end
reduc
sampl
intervari
sinc
like
distribut
atherosclerot
plaqu
homogen
throughout
total
aortic
length
segment
open
divid
sagitt
cut
two
counterpart
counterpart
segment
distribut
two
studi
group
nonblock
control
block
atorvastatin
expos
lumen
final
wash
pb
guarante
potenti
trace
blood
clean
aorta
section
impregn
pb
enrich
glucos
mm
mm
mm
previous
warm
control
group
dmso
polyethylen
glycol
sorbitan
monolaur
v
v
ad
block
group
atorvastatin
mg
dmso
polyethylen
glycol
sorbitan
monolaur
v
v
ad
reach
total
concentr
mm
final
aorta
section
left
incub
min
incub
time
atorvastatin
approx
mbq
ad
group
left
incub
h
final
total
volum
liquid
care
pipet
aorta
section
wash
time
cold
pb
follow
ice
water
slice
care
dri
imag
ge
healthcar
amersham
typhoon
autoradiographi
system
acquir
data
analyz
optiqu
softwar
quantifi
radiotrac
uptak
digit
luminesc
unit
dlu
data
express
mean
standard
deviat
sd
unpair
twotail
test
use
statist
evalu
p
consid
statist
signific
statist
analys
data
perform
use
graphpad
prism
version
window
graphpad
softwar
la
jolla
ca
usa
